Author Topic: (Abst.) Annual disease progression of MS patients: Population-based study  (Read 7 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 7446
  • Location: Pacific Northwest
From PubMed, May 10, 2017:

Quote
Mult Scler. 2017 May 1.

Characterization of annual disease progression of multiple sclerosis patients: A population-based study

Freilich J1, Manouchehrinia A2, Trusheim M3, Baird LG4, Desbiens S4, Berndt E5, Hillert J2.

Author information

1
Department of Management Engineering, Technical University of Denmark, Kongens Lyngby, Denmark/Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA.
2
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
3
Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA/Center of Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA.
4
Center of Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA.
5
Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA.

BACKGROUND:

Previous research characterizing factors influencing multiple sclerosis (MS) disease progression has typically been based on time to disease milestones (Kaplan-Meier, Cox hazard regression, etc.). A limitation of these methods is the handling of the often large groups of patients not reaching the milestone.

OBJECTIVE:

To characterize clinical factors influencing MS disease progression as annual transitions from each Expanded Disability Status Scale (EDSS).

METHOD:

The annual progression of 11,964 patients from the Swedish MS Registry was analysed with 10 multinomial logistic regressions, that is, one for transition from each full EDSS with explanatory variables age, sex, age at onset, time in current EDSS, highest prior EDSS, MS course and treatment.

RESULTS:

All factors (except sex) investigated had statistically significant impacts on transitions from at least one EDSS. However, significance and size of the effect are dependent on the EDSS state of the patient. Greater age, longer time in a state, highest prior EDSS, having progressive MS and treatment had significant impacts, whereas age at onset had minor impact.

CONCLUSION:

Our study confirms that established factors associated with MS disease worsening in time to disease milestones also have impacts on annual progression. This approach adds granularity to what EDSS these factors ... influence.

The last sentence seems to be saying that the researchers' approach adds new dimensions to the significance of EDSS and influences on that score.

https://www.ncbi.nlm.nih.gov/pubmed/28481159







SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics